Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZWOYL)

• Drug Name: ASN51 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMZWOYL

Molecule-Related Drug Atlas

Drug(s) Targeting Beta-N-acetylhexosaminidase (OGA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY3372689	DMA2M7V	Alzheimer disease	8A20	Phase 2	[3]
MK 8719	DMFLP21	Progressive supranuclear palsy	8A00.10	Phase 1	[4]
MK-8719	DMETIBD	Progressive supranuclear palsy	8A00.10	Phase 1	[5]
BIIB113	DM7U1AC	Alzheimer disease	8A20	Phase 1	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-N-acetylhexosaminidase (OGA)	TT2I6UX	OGA_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04759365) A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Oral ASN51 in Healthy Young Adult and Elderly Subjects and Elderly Subjects With Alzheimer's Disease. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Asceneuron
• [3] ClinicalTrials.gov (NCT05063539) Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097.
• [6] ClinicalTrials.gov (NCT05195008) A Phase 1 Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With an Open-Label Target Occupancy Study of BIIB113 in Healthy Participants. U.S.National Institutes of Health.